The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its position within the broader industry now raises questions about future yields . Generic versions are eroding market share, prompting anxieties that betting on companies heavily reliant to Viagra's once-dominant position could be a problematic strategy